Harrow, Inc. Common Stock
HROWHarrow, Inc. (HROW) is a medical technology company specializing in the development and commercialization of advanced microneedle-based systems for the delivery of pharmaceuticals, vaccines, and other therapeutics. The company's innovative approaches aim to improve patient care through minimally invasive, pain-free, and efficient drug administration methods. Harrow's products are designed to enhance compliance, reduce administration costs, and expand access to vital treatments.
Company News
Harrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses...
Harrow (Nasdaq: HROW), a leading ophthalmic disease management solutions provider, announced that management will present at William Blair's 46th Annual Growth Stock Conference on June 3, 2026, in Chicago. The presentation will be webcast live with a 90-day replay available on the company's website.
Harrow (Nasdaq: HROW), an ophthalmic disease management solutions provider, announced a private offering of $50 million in 8.625% senior unsecured notes due 2030. The notes will be issued as additional notes under the same indenture as $250 million in existing notes issued in September 2025. The offering is expected to close on March 27, 2026, wi...
Opaleye Management Inc., a 10% owner of ophthalmic pharma company Harrow, sold 198,572 shares worth $7.8 million on March 3-4, 2026. However, the fund retained approximately 3.7 million shares (nearly 10% ownership), suggesting this was a tactical profit-taking move following post-earnings weakness rather than a strategic exit.
Harrow announced it will report Q4 and full-year 2025 financial results on March 2, 2026, with a conference call scheduled for March 3, 2026. The company reaffirmed its 2025 full-year revenue guidance of $270-$280 million, indicating strong growth. Harrow is expanding its commercial footprint across multiple product lines including VEVYE, IHEEZO,...
